Evidence map›Paper›PMID 42180924›Full record

ArticleTranslational cancer research2026

Establishment and validation of a novel anoikis-related prognostic signature of lung squamous cell carcinoma.

Zhengpan Wei, Kaishang Zhang, Kaiyuan Li, Shaowu Sun, Xu Liu, Wenbo Fan, Zelong Wang, Tianliang Zhao, Tongfa Yan, Bin Yan and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Zhengpan Wei *Department of Thoracic Surgery and Lung Transplantation, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Kaishang Zhang *Department of Thoracic Surgery and Lung Transplantation, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Kaiyuan LiDepartment of Thoracic Surgery and Lung Transplantation, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Shaowu SunDepartment of Thoracic Surgery and Lung Transplantation, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xu LiuDepartment of Thoracic Surgery and Lung Transplantation, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Wenbo FanDepartment of Thoracic Surgery and Lung Transplantation, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zelong WangDepartment of Thoracic Surgery and Lung Transplantation, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Tianliang ZhaoDepartment of Thoracic Surgery and Lung Transplantation, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Tongfa YanDepartment of Thoracic Surgery and Lung Transplantation, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Bin YanDepartment of Thoracic Surgery and Lung Transplantation, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhiqian ZhaoDepartment of Thoracic Surgery and Lung Transplantation, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Qihang ZhaoDepartment of Thoracic Surgery and Lung Transplantation, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Guoqing ZhangDepartment of Thoracic Surgery and Lung Transplantation, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xue PanSchool of Nursing and Health, Zhengzhou University, Zhengzhou, China.
Xiangnan LiDepartment of Thoracic Surgery and Lung Transplantation, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lung squamous cell carcinoma (LUSC) remains a highly lethal malignancy due to its propensity for metastasis and the limited availability of reliable prognostic biomarkers. Anoikis, a detachment-induced cell death mechanism, plays dual roles in tumor suppression and metastasis, yet its prognostic implications in LUSC are poorly characterized. This study aimed to develop an anoikis-related gene (ARG) signature for risk stratification and therapeutic exploration in LUSC. Methods: Transcriptomic data from The Cancer Genome Atlas (TCGA)-LUSC (n=496) and Gene Expression Omnibus (GEO) cohorts (GSE3141/GSE73403; n=121) were analyzed. Differentially expressed ARGs were identified using limma package. Prognostic genes were screened via univariate Cox regression and Least Absolute Shrinkage and Selection Operator (LASSO) regression to construct a risk model. Immune infiltration was evaluated using CIBERSORT, single-sample Gene Set Enrichment Analysis (ssGSEA), and ESTIMATE. Experimental validation included Results: A total of 307 differentially expressed ARGs were identified, with 37 showing prognostic significance. Unsupervised clustering divided LUSC into two subgroups with distinct survival (P<0.001) and immune microenvironments. Cluster B exhibited higher immune and stromal scores but poorer outcomes, enriched in exhausted CD8

Indexed as

anoikis, prognostic modelCSNK2A1Lung squamous cell carcinoma (LUSC)precision oncologytumor microenvironment (TME)

Identifiers

PMID42180924
PMCPMC13190748

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.